| $350M | ||
| $172M | ||
| $127M | ||
| $109M | ||
| $107M | ||
| $100M |
Buys | $0 | 0 | 0 |
Sells | $106,725 | 14 | 100 |
| Parison Amy | SVP, Chief Financial Officer | 0 | $0 | 5 | $6,328 | $-6,328 |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 0 | $0 | 5 | $20,333 | $-20,333 |
| O'Neill Gilmore Neil | CEO | 0 | $0 | 4 | $80,064 | $-80,064 |
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
Over the last 12 months, insiders at Editas Medicine, Inc. have bought $0 and sold $106,725 worth of Editas Medicine, Inc. stock.
On average, over the past 5 years, insiders at Editas Medicine, Inc. have bought $253,868 and sold $595,708 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 45,000 shares for transaction amount of $253,868 was made by Hopfield Jessica (director) on 2024‑05‑13.
| 2026-09-03 | Sale | O'Neill Gilmore Neil | CEO | 5,124 0.0033% | $3.04 | $15,563 | +6.35% | |
| 2026-09-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 709 0.0005% | $3.04 | $2,153 | +6.35% | |
| 2026-09-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 453 0.0003% | $3.04 | $1,376 | +6.35% | |
| 2026-08-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 678 0.0007% | $2.58 | $1,749 | +12.26% | |
| 2026-07-28 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 4,928 0.0051% | $2.67 | $13,158 | +11.45% | |
| 2026-06-03 | Sale | O'Neill Gilmore Neil | CEO | 15,380 0.0153% | $2.70 | $41,543 | +3.60% | |
| 2026-06-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 731 0.0007% | $2.70 | $1,975 | +3.60% | |
| 2026-06-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 464 0.0005% | $2.70 | $1,253 | +3.60% | |
| 2026-03-03 | Sale | O'Neill Gilmore Neil | CEO | 5,394 0.0052% | $2.02 | $10,894 | +39.71% | |
| 2026-03-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 749 0.0007% | $2.02 | $1,513 | +39.71% | |
| 2026-03-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 474 0.0005% | $2.02 | $957 | +39.71% | |
| 2025-12-03 | Sale | O'Neill Gilmore Neil | CEO | 5,603 0.006% | $2.15 | $12,064 | +11.81% | |
| 2025-12-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 713 0.0008% | $2.15 | $1,535 | +11.81% | |
| 2025-12-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 461 0.0005% | $2.15 | $993 | +11.81% | |
| 2025-09-03 | Sale | O'Neill Gilmore Neil | CEO | 5,592 0.0065% | $2.60 | $14,517 | +8.20% | |
| 2025-09-03 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 710 0.0008% | $2.60 | $1,843 | +8.20% | |
| 2025-09-03 | Sale | Parison Amy | SVP, Chief Financial Officer | 458 0.0005% | $2.60 | $1,189 | +8.20% | |
| 2025-08-07 | Sale | Parison Amy | SVP, Chief Financial Officer | 679 0.0008% | $2.58 | $1,752 | +7.23% | |
| 2025-07-31 | Sale | Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 5,121 0.0061% | $2.49 | $12,757 | +5.58% | |
| 2025-06-03 | Sale | O'Neill Gilmore Neil | CEO | 15,192 0.0172% | $1.72 | $26,196 | +40.66% |
| O'Neill Gilmore Neil | CEO | 243189 0.1585% | $785,500.47 | 0 | 12 | |
| Burkly Linda | EVP, CHIEF SCIENTIFIC OFFICER | 61660 0.0402% | $199,161.80 | 0 | 10 | |
| Parison Amy | SVP, Chief Financial Officer | 13839 0.009% | $44,699.97 | 0 | 8 | |
| Polaris Venture Management Co. VI, L.L.C. | 10 percent owner | 3797144 2.4743% | $12.26M | 0 | 9 | |
| Bitterman Kevin | director | 2797144 1.8227% | $9.03M | 0 | 10 | |
| VIKING GLOBAL INVESTORS LP | 2729808 1.7788% | $8.82M | 1 | 0 | ||
| VIKING GLOBAL PERFORMANCE LLC | 2729808 1.7788% | $8.82M | 1 | 0 | ||
| Bosley Katrine | President and CEO | 1204966 0.7852% | $3.89M | 0 | 26 | |
| Flynn James E | 10 percent owner | 954700 0.6221% | $3.08M | 1 | 0 | +20.25% |
| Mei Baisong | EVP, CHIEF MEDICAL OFFICER | 133354 0.0869% | $430,733.42 | 0 | 6 | |
| Glucksmann Alexandra | Chief Operating Officer | 117788 0.0768% | $380,455.24 | 0 | 3 | |
| Lucera Erick | EVP, CHIEF FINANCIAL OFFICER | 112720 0.0735% | $364,085.60 | 0 | 2 | |
| ROBERTSON MICHELLE | EVP, CHIEF FINANCIAL OFFICER | 106610 0.0695% | $344,350.30 | 0 | 12 | |
| MULLEN JAMES C | CEO | 75898 0.0495% | $245,150.54 | 2 | 2 | <0.0001% |
| Eaton Bruce | EVP, CBO AND CTO | 74791 0.0487% | $241,574.93 | 0 | 23 | |
| Hopfield Jessica | director | 67700 0.0441% | $218,671.00 | 4 | 0 | <0.0001% |
| Shearman Mark S | EVP, CHIEF SCIENTIFIC OFFICER | 65559 0.0427% | $211,755.57 | 0 | 2 | |
| Collins Cynthia | CEO | 43760 0.0285% | $141,344.80 | 0 | 3 | |
| Nikolic Boris | director | 35000 0.0228% | $113,050.00 | 1 | 0 | +77.16% |
| Albright Charles | EVP/Chief Scientific Officer | 24907 0.0162% | $80,449.61 | 0 | 14 | |
| Michaels Lisa Anne | EVP/Chief Medical Officer | 18432 0.012% | $59,535.36 | 0 | 1 | |
| Cox Gerald Frank | Chief Medical Officer | 4000 0.0026% | $12,920.00 | 1 | 0 | +77.16% |
| STARR KEVIN P | 10 percent owner | 0 0% | $0 | 0 | 1 | |
| Hack Andrew A. F. | Chief Financial Officer | 0 0% | $0 | 0 | 21 | |
| Myer Vickesh | Chief Technology Officer | 0 0% | $0 | 0 | 18 |
$31,123,523 | 108 | 6.46% | $441.02M | |
$2,481,409 | 33 | 201.68% | $464.66M | |
$31,271,604 | 28 | 28.69% | $540.6M | |
$2,516,932 | 19 | -15.78% | $461.19M | |
$112,238,340 | 19 | 39.16% | $514.11M | |
$1,057,969 | 14 | 68.06% | $449.65M | |
$13,258,734 | 9 | 18.72% | $435.61M | |
Editas Medicine, Inc. (EDIT) | $6,847,110 | 9 | 5.96% | $495.68M |
$5,529,561 | 8 | 5.30% | $522.59M | |
$13,043,783 | 8 | 732.82% | $565.8M | |
$62,616,785 | 8 | -7.00% | $580.23M | |
$17,675,244 | 7 | 92.20% | $486.09M | |
$21,792,890 | 6 | 75.72% | $558.08M | |
$164,999,952 | 5 | -44.44% | $547.08M | |
$4,745,999 | 5 | -4.91% | $591.84M | |
$209,740 | 4 | -1.93% | $466.56M | |
$1,746,565 | 4 | -29.05% | $454.01M | |
$3,850,000 | 1 | -51.32% | $462.17M | |
$20,020,000 | 1 | -75.24% | $501.56M |
| Increased Positions | 79 | +35.43% | 12M | +28.16% |
| Decreased Positions | 81 | -36.32% | 5M | -10.63% |
| New Positions | 32 | New | 2M | New |
| Sold Out Positions | 22 | Sold Out | 659,422 | Sold Out |
| Total Postitions | 221 | -0.9% | 50M | +17.53% |
| Blackrock, Inc. | $16,441.00 | 8.18% | 8.02M | +1M | +17.58% | 2025-09-30 |
| Vanguard Group Inc | $14,280.00 | 7.11% | 6.97M | -193,874 | -2.71% | 2025-09-30 |
| Nuveen, Llc | $4,288.00 | 2.13% | 2.09M | +1M | +120.21% | 2025-09-30 |
| Geode Capital Management, Llc | $4,182.00 | 2.08% | 2.04M | +75,868 | +3.86% | 2025-09-30 |
| State Street Corp | $3,946.00 | 1.96% | 1.93M | +78,175 | +4.23% | 2025-09-30 |
| Two Sigma Investments, Lp | $3,248.00 | 1.62% | 1.58M | +614,229 | +63.33% | 2025-09-30 |
| Renaissance Technologies Llc | $2,619.00 | 1.3% | 1.28M | +389,000 | +43.79% | 2025-09-30 |
| Two Sigma Advisers, Lp | $2,470.00 | 1.23% | 1.21M | +264,400 | +28.11% | 2025-09-30 |
| Morgan Stanley | $2,230.00 | 1.11% | 1.09M | -332,776 | -23.42% | 2025-09-30 |
| Bank Of America Corp /De/ | $2,100.00 | 1.05% | 1.02M | -55,456 | -5.14% | 2025-09-30 |